The latest news:

Court of Appeals Upholds Judgment in ImmuDyne's Favor
Tuesday June 23, 2009

The Court of Appeals for the Fourth District of Texas issues an OPINION that upholds the earlier Judgment that ImmuDyne, Inc. (not BioPolymer Engineering d/b/a Biothera) is the owner of the following seven patents: (1) U.S. Patent No. 5,576,015 ("the '015 patent"), (2) U.S. Patent No. 5,702,719 ("the '719 patent"), (3) U.S. Patent No. 5,705,184 ("the '184 patent"), (4) U.S. Patent No. 5,519,009 ("the '009 patent"), (5) U.S. Patent No. 5,397,773 ("the '773 patent"), (6) Europatent No. 0,500,718 B1; and (7) Canadian Patent 2072145C (collectively, "the disputed patents").

The Court also upheld that ImmuDyne (Pink Sheets:IMMD - News) held an exclusive license to the '015 patent, '009 patent, and '773 patent beginning in 1998. Concerning a license issue only on the '184 and '719 patents, the Court of Appeals ordered this matter to be returned to the trial court for further evidence. ImmuDyne expects to fully prevail on this issue at the trial court. In addition, ImmuDyne cancelled any such possible conflicting license to Biothera due to Biothera's failure to pay required royalties. Thus, ImmuDyne does not view this matter as material going forward.

Due to this one issue regarding licenses, the Court of Appeals remanded the award of attorneys fees for further consideration by the trial court. The Court of Appeals did uphold the basis for at least $325,000 in attorney's fees in ImmuDyne's favor, and ImmuDyne expects to prevail on this matter as well.

ImmuDyne is the only lawful seller of products based upon these patents.

About ImmuDyne(r)

ImmuDyne shares trade under the ticker symbol IMMD (PK) and the Company can be found on the web at www.immudyne.com

Cautionary language regarding Forward-Looking Statements

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

Contact:
ImmuDyne®, Inc.
Mark McLaughlin
1-888-246-6839 ext. 310
markmcl@immudyne.com